Join Yasmin Schlegel’s Journey Against Breast Cancer Recurrence
Beloved friends and supporters
United States, 16th Jan 2024, King NewsWire – I’m a U.S. Army veteran and a survivor of Triple Negative Breast Cancer (TNBC). Diagnosed in August 2021, my journey has been one of resilience and determination. I underwent a rigorous treatment plan, enduring 5 months of intravenous chemotherapy with immunotherapy, followed by a lumpectomy in March 2022, and 30 radiation sessions in June 2022. Encouragingly, my scans in August 2022 were positive, prompting the addition of Xeloda to eliminate any residual cancer cells. I successfully completed the Xeloda treatments in February 2023.
Despite these efforts, a recent November 2023 mammogram revealed small calcifications near the surgical bed, indicating a breast cancer recurrence. To combat this setback, I am now exploring alternative treatments both within and outside the U.S. One promising option is Dendritic Cell Therapy, a groundbreaking approach in Europe.
Dendritic Cell Therapy involves utilising dendritic cells and a patient’s blood sample, combining them in a lab. After a week of incubation, the reinvigorated dendritic cells are reintroduced into the body, acting as a personalised vaccine to combat and reduce cancer recurrences.
As I embark on this new phase of treatment, I am reaching out to seek your support in making Dendritic Cell Therapy and other complementary treatments possible. Your contribution will play a crucial role in enhancing my chances of overcoming this recurrence and achieving a healthier future.
Join me in this fight against cancer, and together, let’s make a difference.
Thanks for your support.
Yasmin Schlegel
For media inquiries, please contact:
Yasmin Schlegel
703-474-4066
yasmin.schlegel@gmail.com
http://spot.fund/s9wrwsc
Media Contact
Organization: Spotfund.
Contact Person: YASMIN SCHLEGEL
Website: http://spot.fund/s9wrwsc
Email: Send Email
Country: United States
Release Id: 1601248921
The post Join Yasmin Schlegel’s Journey Against Breast Cancer Recurrence appeared first on King NewsWire. It is provided by a third-party content provider. King Newswire makes no warranties or representations in connection with it.
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No News Postbox journalist was involved in the writing and production of this article.
